 |
Dr. H. Richard Alexander Jr. - Baltimore, Maryland
- Dr. Alexander is an internationally recognized cancer surgeon
and surgical oncologist at the University of Maryland Marlene and
Stewart Greenebaum Cancer Center. He is also the associate
chairman for clinical research in the University of Maryland
Department of Surgery. His research interests include perfusion
techniques to treat patients with advanced cancers of the limb,
liver, and peritoneal cavity. Dr. Alexander was formally the
deputy director of the NCI's Center for Cancer Research.
University of Maryland Medical Center
Greenebaum Cancer Center
22 S. Greene Street
Baltimore, MD 21201
Phone: 410.605.7233 (VA Baltimore)
email: HRAlexander@smail.umaryland.edu
Baltimore VA Medical Center
10 North Greene Street
Baltimore, MD 21201
(410) 605-7000
800-463-6295
http://www.umm.edu/news/releases/hr_alexander.html
|
 |
Dr. Robert Cameron - Los Angeles, California
- Dr. Cameron is a surgical oncologist with expertise in
treating mesothelioma patients at the UCLA Medical School.
- Dr. Robert Cameron is a member of the Scientific Advisory
Board for the Pacific
Heart, Lung, & Blood Institute (PHLBI, www.phlbi.org). Dr.
Cameron has been at the forefront of developing innovative
therapies for extending the lives of mesothelioma patients. Dr.
Cameron's research plan for PHLBI includes programs involving
Immunotherapy and Screening/Early Detection/Prevention. Dr.
Cameron's research plan also includes investigation into
much-needed administrative improvements in medical care which
will provide patients with additional knowledge, security, and
control regarding their treatment. Click here to see the
details of Dr. Cameron's research plan.
- 11818 Wilshire Blvd., Suite 200
Los Angeles, California 90025
Phone: 310.794.7333 or 310.231.2130
email: rcameron@mednet.ucla.edu.
- "Improved
Survival with Interferon Alpha Maintenance Therapy Following
pleurectomy / decortication and Radiation for Malignant Pleural
Mesothelioma," as presented by Dr. Robert Cameron to the
Society of Thoracic Surgeons, January 30, 2006.
- EPP vs P/D: The Great
Debate. Dr. Cameron favors the Pleurectormy/Decortication
(10/29/06)
- Anatomy of a
Successful P/D (photos). Dr. Robert Cameron, September 13,
2005
- "Rational Versus Radical
Therapy For Mesothelioma: A New Approach," Dr. Robert
Cameron, UCLA Medical School, presented at MARF Symposium in Las
Vegas, October 16, 2004. Copyright of
Dr. Robert Cameron. Do not copy without permission (11/18/04)
- UCLA Proposes Comprehensive Mesothelioma Translational Research
Program (5/10/04)
|
 |
Dr. Alexander Farivar - Seattle, Washington
- Dr. Farivar is the Director of Pleural Disease at the Swedish Cancer Institute in Seattle. He has expertise in
Esophageal and Thoracic Surgery at the Swedish Cancer Institute in Seattle.
- Swedish Cancer Institute
1221 Madison Street suite 400
Seattle, WA 98104
Phone: 206.215.6800
- For more, click here.
|
| no photo available |
Dr. David Jablons - San Francisco, California
|
 |
Dr. Larry Kaiser -
Philadelphia, Pennsylvania
|
 |
Dr. Brian Loggie -
Omaha, Nebraska
|
 |
Dr. Harvey Pass - New York,
New York
- Dr. Harvey Pass is Professor and Chief of the Division of
Thoracic Surgery and Thoracic Oncology at the New York University
School of Medicine and Comprehensive Cancer Center. Dr. Pass has
studied pleural mesothelioma since 1988 when he was the Head of
Thoracic Oncology and Senior Investigator of the Surgery Branch
of the National Cancer Institute in Bethesda. Dr. Pass combines
cytoreductive surgery, either EPP or pleurectomy, with innovative
or standard adjuvant therapies including novel antiangiogenesis
inhibitors postoperatively or chemotherapy combinations. His
Thoracic Oncology laboratory is pursuing the study of proteins
(proteomics) and gene expression profiles in mesothelioma to
develop new early detection strategies, as well as designing
alternate innovative treatments which use novel proteins as
targets for mesothelioma. More...
- Curriculum Vitae (resume), Dr. Harvey Pass. March 26, 2003
- Dr. Pass is the Chairman of the Science Advisory Board of the
Mesothelioma Applied Research Foundation (MARF).
- Professor and Chief, Division of Thoracic Surgery and
Thoracic Oncology
Department of Cardiothoracic Surgery
NYU School of Medicine and Comprehensive Cancer Center
530 1st Avenue, 9V
New York, New York 10016
Phone: 212.263.7417
email: passh01@med.nyu.edu
- Malignant Pleural
Mesothelioma: Surgical Roles and Novel Therapies,
preface by RGW (2/7/02)
- Photo Dynamic Therapy, Surgery by Dr. Harvey
Pass and Chemotherapy Help 35 Year Old's Battle Against
Mesothelioma
- Preoperative Tumor
Volume is Associated With Outcome in MM, (2/8/98)
- Update on Dr.
Harvey Pass' Research: (10/6/97)
|
 |
Dr. Lary A. Robinson - Tampa, Florida
- Dr. Robinson is a thoracic surgical oncologist with expertise in treating
mesothelioma patients.
- Dr. Robinson is on the Science Advisory Board of the
Mesothelioma Applied Research Foundation (MARF).
H. Lee Moffitt Cancer Center & Research Institute
12902 Magnolia Drive
Tampa, Florida 33612-9497
Phone: 813.979.3050
email: robinson@moffitt.usf.edu.
http://www.moffitt.usf.edu
- Thoracic Surgeon, H. Lee Moffitt
Cancer Center & Research Institute, Tampa, Florida
|
| no photo available |
Dr. Valerie Rusch - New York, New York
- Memorial Sloan-Kettering Cancer Center
1275 York Avenue
New York, NY 10021
Phone: 212.639.5873
email: ruschv@mskcc.org
- Memorial Sloan-Kettering Cancer Center in New York City. http://www.mskcc.org
|
 |
Dr. W. Roy Smythe -
Temple, Texas
- Dr. W. Roy Smythe is involved in the surgical diagnosis and
treatment of mesothelioma patients. He has designed a pilot
protocol at M. D. Anderson for malignant pleural mesothelioma
involving aggressive surgical therapy followed by intensity
modulated radiation therapy (IMRT). In the laboratory, he was
involved in the initial research work evaluating gene therapy for
this disease in the mid 1990's at the University of
Pennsylvania. He is currently evaluating a number of novel gene
therapy and molecular approaches to the treatment of this
disease, and hopes to bring one or more of these to the clinic in
the next year.
- Curriculum Vitae (resume),
Dr. W.Roy Smythe. October 16, 2001
- Dr. Smythe is on the Science Advisory Board of the
Mesothelioma Applied Research Foundation (MARF).
- Preclinical Data of Introgen's INGN 241 Demonstrate Broad Anti-Cancer
Activity In Multiple Tumor Types as Monotherapy and in
Combination; Update on Gene Therapy Research at MDA under Dr.
Roy Smythe (6/14/01)
- Dr. W. Roy Smythe
Professor & Chairman
Texas A&M University Health Sciences Center
Scott & White Hospital and Clinic
Department of Surgery
2401 South 31st Street
Temple, TX 76501
Phone: 254.724.2595
Fax: 254.724.2786
email: rsmythe@swmail.sw.org
|
 |
Dr. David Sugarbaker - Boston, Massachusetts
- Dr. Sugarbaker is a surgical oncologist with expertise in
treating mesothelioma patients. Dr. Sugarbaker has pioneered the
"tri-modal" therapy approach.
Brigham & Womens Hospital
75 Francis Street, Boston
Massachusetts 02115
Phone: 617.732.6824
email: djsugarbak@bic.bwh.havard.edu.
- Summary of Dr. Sugarbaker's
Results Using Tri-Modal Therapy on 183 Patients from 1980 to
1997.
- Multimodality Management of MM: Dr.
David Sugarbaker, January 1999
- Current Therapy for Mesothelioma,
Sugarbaker et al, 1997
The Division of Thoracic Surgery at the Brigham and
Women's Hospital in Boston Massachusetts provides
diagnostic and treatment services to patients with benign and
malignant neoplasms and other disorders of the lung, esophagus,
mediastinum and chest wall. Their website provides complete
review of services available, how to set up an appointment,
whom to call, and how to prepare for surgery and rehabilitate
afterwards. Check it out. http://www.chestsurg.org
|
| no photo available |
Dr. Paul Sugarbaker - Washingon , D. C.
- Sugarbaker Oncology Associates, P.C.
110 Irving St., NW
Washington, DC 20010
Phone: 202.877.3908
email: n/a
- Sugarbaker Oncology Associates, Washington Cancer Institute, Washington Hospital Center, Washington, D.C. "We specialize in the surgical treatment of cancers that arise in the gastrointestinal tract, such as abdominal (Peritoneal) mesotheliomas."
|
 |
Dr. Robertt Taub - New York,
New York
- Dr. Taub is a medical oncologist who directs the Connective
Tissue Oncology Program at the Herbert Irving Comprehensive
Cancer Center, where there are a number of ongoing multimodality
studies of patients with pleural and peritoneal mesothelioma.
- Dr. Taub is on the Science Advisory Board of the Mesothelioma
Applied Research Foundation (MARF).
Columbia University College of Physicians and Surgeons
161 Fort Washington Avenue
New York, New York 10032
Phone: 212.305.4076
email: rnt1@columbia.edu
- Phase II
Trial of Combined Resection, Intraperitoneal
Chemotherapy, and Whole Abdominal Radiation for Treatment of
Peritoneal Mesothelioma (11/14/01)
- New Trial Using Tri-Modal Therapy for
Peritoneal Mesothelioma in New York with Dr. Robert N. Taub.
|
 |
Dr. Eric Vallieres - Seattle, Washington
- Dr. Vallières is a surgical oncologist who since 1997
has been the principal investigator of a Phase II multi-modal
trial for mesothelioma patients at the University of Washington
Medical Center. He now practices at the Swedish Cancer Institute.
- Dr. Vallières is on the Science Advisory Board of the
Mesothelioma Applied Research Foundation (MARF).
University of Washington School of Medicine
Eric Vallières MD FRCSC
Thoracic Oncology
Swedish Cancer Institute
1221 Madison Street suite 400
Seattle, WA 98104
Phone: 206.-215.6800
Fax: 206.215.6801
email: eric.vallieres@swedish.org
- Dr. Eric Vallières: Engaged on all Fronts. Seattle, Washington
|
| |
|
 |
Dr. Claire Verschraegen - Albuquerque, New Mexico
- Dr. Verschraegen is an oncologist and Director of Experimental Therapeutics at the University of New Mexico.
- Dr. Verschraegen is on the Science Advisory Board of the Mesothelioma Applied Research Foundation (MARF).
- Director of Experimental Therapeutics
Cancer Research and Treatment Center
University of New Mexico
900 Camino de Salud NE
Albuquerque NM 87131
Phone: 505.272.5837
email cverschraegen@salud.unm.edu
|
 |
Dr. Nicholas Vogelzang - Las Vegas, Nevada
- Dr. Vogelzang is a thoracic surgical oncologist with interests in clinical trials in genitourinary malignancies and mesothelioma. He is a recognized expert in new therapies for patients with metastatic kidney cancer, including genetic therapy, new cytokine therapy, and combination.
- Therapeutic Progress in Malignant Mesothelioma by Nicholas J. Vogelzang, MD. A summary of the diagnosing, staging, treatment approaches (including pemetrexed) and additional trials. (4/27/05)
- Dr. Vogelzang is on the Board of Directors of the Mesothelioma Applied Research Foundation (MARF).
Nevada Cancer Institute
10000 W.Charleston Blvd., Suite 260
Las Vegas, NV 89135
Phone: 702.821.0000
email nvogelza@nvcancer.org
www.nevadacancerinstitute.org
- ASCO Reports on Intracavitary Hyperthermic Chemo, FDG-PET Scan Prognostication, and Alimta/Cisplatin Quality of Life (6/12/03)
- Unresectable Mesothelioma: A New Standard of Care (5/29/02)
"Mesothelioma of the pleura, peritoneum,pericardium, and tunica vaginalis is a very rare malignancy which takes the lives of 3-5 wonderful people per day in the USA. It cause significant suffering, pain, shortness of breath, abdominal bloating and weight loss which are often resistant to all medical care. It is a disease which most medical,surgical and radiation oncologists have little or no experience in treating due to its rarity, and sadly many such physicians do not wish to become involved in the treatment of the disease because treatments have been so ineffective. In spite of this sad state of affairs a few oncologists have worked and struggled for the past 10-20 years to improve the care and outcome of such patients. We are delighted to finally have a support group such as MARF helping with the struggle. Just as the breast, prostate and colon cancer support groups have mobilized research funds, so MARF will do. Patients and their families must get involved and MARF is a way for them to do so." Dr. Nicholas Vogelzan |
|
| |
|